Health care startups that raised Series C in Hangzhou, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Healsun Biopharm | Hangzhou | Series C | $27.8M | 2025-11-19 |
| DIAGENS | Hangzhou | Series C | $14.1M | 2023-12-29 |
| LYNK Pharmaceuticals | Hangzhou | Series C | $16.7M | 2023-09-21 |
4 rows of the CSV in 5 of its 18 columns.
- The 33 health care startups in Hangzhou, China whose last round is Series C have raised $1.3B in total.
- 8 of them closed their most recent round in the last 12 months, $221.7M combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- Puhua Capital is an investor in 2 of them, more than any other fund.
- Biotech is the most common other sector, with 20 companies (61%).
- 3% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 51 to 100 employees (33% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
4 of 33| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| DIAGENS | DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. | Biotech | Series C | $14.1M | 2023-12-29 | Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 | 51 to 100 | 2014 | |
| LYNK Pharmaceuticals | LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. | Biotech | Series C | $16.7M | 2023-09-21 | Legend Capital, Kaitai Capital, New Alliance Capital +2 | 11 to 50 | 2018 |
Table 1. Health care startups that raised Series C in Hangzhou, China: the 4 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 33.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
Table 2. Health care startups that raised Series C in Hangzhou, China: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Puhua Capital | Venture capital firm | Hangzhou, China | 2 | 6% | ||
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 1 | 3% | 1 | AusperBio |
| 3 | Hankang Capital | Venture capital firm | Shanghai, China | 1 | 3% | 1 | AusperBio |
| 4 | BioVenture | Venture capital firm | Suzhou, China | 1 | 3% | 1 | AusperBio |
| 5 | Genesis Capital | Private equity firm | Central, Hong Kong | 1 | 3% | 1 | AusperBio |
| 6 | BioTrack Capital | Venture capital firm | Shanghai, China | 1 | 3% | 1 | Shenluo Medical |
| 7 | OrbiMed | Private equity firm | New York, United States | 1 | 3% | 1 | Shenluo Medical |
| 8 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 1 | 3% | 1 | Healsun Biopharm |
| 9 | Haibang Capital | Venture capital firm | Hangzhou, China | 1 | 3% | 1 | Healsun Biopharm |
| 10 | Dongfang Jiafu | Private equity firm | Hangzhou, China | 1 | 3% | 1 | Healsun Biopharm |
| 11 | Yinxinggu Capital | Venture capital firm | Hangzhou, China | 1 | 3% | 1 | Healsun Biopharm |
| 12 | Haitong Capital | Private equity firm | Lisbon, Portugal | 1 | 3% | 1 | Healsun Biopharm |
| 13 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 1 | 3% | ||
| 14 | CASH Capital | Private equity firm | Beijing, China | 1 | 3% | ||
| 15 | ZSVC | Private equity firm | Beijing, China | 1 | 3% |
Table 3. Health care startups that raised Series C in Hangzhou, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
Table 4. Health care startups that raised Series C in Hangzhou, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 33 | 100% | $27.8M |
Table 5. Health care startups that raised Series C in Hangzhou, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 2 | 25% | $149.6M |
| June 2026 | 2 | 25% | $44.3M |
| May 2026 | 1 | 12% | |
| March 2026 | 1 | 12% | |
| December 2025 | 1 | 12% | |
| November 2025 | 1 | 12% | $27.8M |
Table 6. Health care startups that raised Series C in Hangzhou, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 6 | 18% | $193.9M |
| 2025 | 7 | 21% | $174.1M |
| 2024 | 3 | 9% | $14.0M |
| 2023 | 2 | 6% | $30.8M |
| 2022 | 2 | 6% | |
| 2021 | 6 | 18% | $390.6M |
Table 7. Health care startups that raised Series C in Hangzhou, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 1 | 3% |
| 2015 to 2019 | 16 | 50% |
| 2010 to 2014 | 13 | 41% |
| Before 2010 | 2 | 6% |
Table 8. Health care startups that raised Series C in Hangzhou, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 6% |
| 11 to 50 | 7 | 21% |
| 51 to 100 | 11 | 33% |
| 101 to 250 | 5 | 15% |
| 251 to 500 | 5 | 15% |
| 501 to 1,000 | 3 | 9% |
Table 9. Health care startups that raised Series C in Hangzhou, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series C and its headquarters is in Hangzhou, China. On 16 November 2026 that is 33 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 4 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 33 rows: 10 have no round amount, 0 no city and 6 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Hangzhou, China whose last round is Series C are on the list?
- 33, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 33 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.